Please login to the form below

Not currently logged in
Email:
Password:

Medical Research Council launches disease compounds research library

Teams up with AZ, GSK, Janssen, Pfizer, Takeda and UCB

MRCThe Medical Research Council (MRC) has teamed up with six pharma companies to create a disease compounds library for academic researchers from around the world.

The collection, which is the latest product of the MRC's Industry Asset Sharing Initiative, comprises 47 deprioritised compounds contributed by AstraZeneca, GlaxoSmithKline, Janssen, Pfizer, Takeda and UCB.

Both pre-clinical and clinical compounds are featured in the MRC library, which includes molecules developed for ADHD, cancer, diabetes and narcolepsy and is the largest resource of its kind.

Also on offer is up to £5m in funding for research studies that use the compounds to investigate the mechanics of diseases, with a view to the development of new medicines.

Commenting on the research library partnership, MRC's director of translational research and industry Dr Chris Watkins said: “The MRC is a world-leader in forging links between industry and universities and academics.

“Academic partners benefit from working hand-in-hand with industry counterparts, large and small, to join in this innovative MRC collaboration designed to speed up the translation of basic science into real health benefits for patients.”

This latest initiative builds on an earlier resources-sharing collaboration between the MRC and AZ, launched in 2014. Located at AZ's research and development site in Cambridge, the Centre for Lead Discovery provides researchers with access to its in-house compound library and compound screening capabilities.

UCB has also previously joined forces with the MRC, working with the Council to provide UK scientists with access to the company's technology platform to aid the discovery of new monoclonal antibodies.

The deadline for expressions of interest for MRC's latest compound collection venture is 12 October 2016. To apply, contact Dr Jo Latimer.

Article by
Rebecca Clifford

20th September 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics